Chinese drug manufacturer InventisBio bags $147m led by Hillhouse Capital

Source: Volodymyr Hryshchenko/Unsplash

Clinical stage, small molecule drugs maker InventisBio Inc., has garnered 1 billion yuan ($147 million) in a Series D funding round led by Asia focused private equity firm Hillhouse Capital.

New investors who participated in the round included Qiming Venture Partners, MatrixPartners China, Hong Kong-based investment firm Janchor Partners, healthcare-focused AIHC Capital, DYEE Capital, and Utrust’s asset manager E Fund, InventisBio announced on Monday

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter